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After completing primary treatment, it is standard practice in most
countries for breast cancer patients to be followed in specialist
outpatient clinics during the disease-free interval. This practice of
post-treatment surveillance has recently come under close scrutiny
(Dewar, 1995; Donegan, 1995; Loprinzi, 1995; Breast Cancer
Surveillance Expert Panel, 1997). Studies to evaluate its effective-
ness have used a ￿less intensive￿ specialist follow-up regimen as
the comparator (GIVIO Investigators, 1994; Rosselli Del Turco et
al, 1994). No previous studies have evaluated prospectively the
cost effectiveness of this practice of long-term follow-up of breast
cancer patients.
We conducted a randomized controlled trial (RCT) comparing
specialist follow-up with follow-up by the patient￿s own general
practitioner (Grunfeld et al, 1996). The results showed no increase
in delay in diagnosing recurrence and reinitiating specialist care as
a result of primary care follow-up. As has been reported in
previous studies (Clark and Morris, 1981; Hughes, 1985; Tomin
and Donegan, 1987; McWhinney et al, 1990; Worster et al, 1995),
the results of the RCT (Grunfeld et al, 1996) showed that most
recurrences are detected in the interval between regularly sched-
uled follow-up appointments, and many are presented to the
general practitioner irrespective of the formal follow-up arrange-
ments. The results also showed no increase in anxiety or deteriora-
tion in health-related quality of life (HRQOL) (Grunfeld et al,
1996). We report here the results of the economic evaluation to
assess the relative costs of the two alternative schemes of follow-
up that was conducted concurrent with the RCT. Because the RCT
showed no important differences in the primary clinical outcomes,
the form of economic evaluation was cost minimization whereby
the two schemes are examined for the least costly alternative
(Drummond et al, 1997).
PARTICIPANTS AND METHODS
Participants and methods for the RCT
Participants were 296 women with breast cancer in remission
receiving regular follow-up at two district general hospitals in
England. These women were taking part in an RCT to evaluate a
primary-care-based system of routine breast cancer follow-up,
whereby they were randomized to one of two groups: continued
routine follow-up in hospital outpatient clinics according to usual
practice (hospital group) or routine follow-up from their own
general practitioner (general practice group). Ethical approval to
conduct the study was obtained from the local research ethics
committees. The recommended follow-up regimen was the same
for women in both groups and involved periodic physician visits
for a breast cancer check-up, routine surveillance mammograms
(the frequency depended on initial treatment and age), and diag-
nostic testing only if clinically indicated. A full description of
study participants, study methods and results of the primary
outcomes of time to diagnosis of recurrence and HRQOL have
been reported previously (Grunfeld et al, 1996). Data collection
for economic evaluation was an integral part of the RCT.
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The perspective of the economic evaluation considered costs to the
health service (particularly, the costs of follow-up visits and diag-
nostic tests) and costs to the patients (such as lost earnings and out-
of-pocket expenses). Valuation of resources was based on unit
costs from the providers and national averages. All costs are
expressed in 1994 UK £s. Discounting was not considered to be
relevant to this analysis, which concerns an 18-month time period.
Health service costs
Information on health service resource use was collected prospec-
tively at both hospital and general practice visits by means of a
record-of-visit form. This was completed at all consultations
possibly related to breast cancer by doctors for patients in both
groups and provided details of the frequency of visits, the duration
of each visit, and the diagnostic tests ordered at each visit. The
study hospitals provided unit costs for each type of test and for an
average outpatient consultation (based on the total annual running
and capital costs of the department averaged across the total
number of attendances); the equivalent total costs for an average
general practice consultation was taken from national averages.
In the analysis of costs, the average of the unit costs for the
diagnostic tests, procedures and outpatient consultations provided
by the two study hospitals was used.* For estimates of the general
practitioner consultations, UK Department of Health estimates of
the cost of a consultation were adjusted to allow for the differences
in the average length of surgery and home consultations (Wilson,
1991). Using this approach, a cost per minute of £1.15 was esti-
mated. To calculate a cost per GP consultation, the cost per minute
was then applied to the length of each consultation.
Patient costs
A questionnaire to collect data on costs incurred by the patient was
developed specifically for this study. The cost questionnaire
related to costs associated with the patient￿s most recent breast
cancer follow-up visit, and included questions about out-of-pocket
expenses, lost earnings as a result of time off work, time spent in
attending the follow-up visit, and costs incurred by accompanying
persons. When patients, or those accompanying them, indicated
that they had lost earnings over a specified period as a result of a
follow-up visit, the cost to them of this visit was estimated by
applying appropriate national average hourly wage rates￿.
The cost questionnaire formed part of the questionnaire package
containing the instruments measuring HRQOL, described previ-
ously (Grunfeld et al, 1996). The questionnaire package was
posted to study participants at three points during the 18-month
study period: baseline (before randomization when all follow-up
appointments were in hospital outpatient clinics), midtrial and at
the end of the trial. One reminder was sent if the questionnaire had
not been returned within 2 weeks. Participants completed the
midtrial questionnaire within 10 days of a follow-up visit. As there
were no important differences in the results obtained at midtrial
from those obtained at the end of the trial, midtrial results are
reported here because they were more closely linked to a recent
follow-up appointment.
Analysis
The two-tailed t-test was used to assess the significance of
between group differences in means. The c2 test was used to assess
the significance of between group differences in proportions.
Statistical analysis was performed using the software package
Statistical Package for the Social Sciences (SPSS, version 6.1.2).
Confidence intervals were calculated using the statistical program
CIA (Garner, 1991). All analysis was on an intention-to-treat
basis.
Response rates
Completed record-of-visit forms were returned by physicians for
100% (148 out of 148) of patients in the general practice group
(i.e. at least one form was received for each patient) and for 95.3%
(141 out of 148) of patients in the hospital group.
The baseline cost questionnaire was completed by 99.3% (147
out of 148) of patients in the general practice group and 95.3%
(141 out of 148) of patients in the hospital group. By midtrial, four
patients had died in the general practice group and five had died in
the hospital group. The adjusted response rate for the midtrial cost
questionnaire was 97.2% (140 out of 144) and 88.7% (126 out of
142) respectively. At the end of the study period, a total of six
patients had died in the general practice group and one had moved
and so was lost to follow-up, whereas a total of 12 patients had
died in the hospital group and one had moved and so was lost to
follow-up. The adjusted response rate for the end of the trial cost
questionnaire was 97.2% (137 out of 141) in the general practice
group and 88.1% (119 out of 135) in the hospital group.
As the adjusted response rate in the hospital group had fallen to
just above 88% while remaining above 97% in the general practice
group, non-respondents in the hospital group were compared on
baseline characteristics and selected domains of the HRQOL
instruments. There were no significant differences between non-
respondents and respondents on any of these variables.
RESULTS
Health service resource use and costs
During the 18 months of the study, general practice patients were
seen significantly more frequently (mean of 3.4 follow up visits)
than were specialist patients (mean of 2.8 follow-up visits) (differ-
ence 0.6; 95% CI 0.3—0.9; P < 0.001). Each follow-up visit was
longer in the general practice group (mean 10.5 min) than in the
hospital group (mean 7.4 min) (difference 3.1; 95% CI 2.6—3.6;
P < 0.001), based on physicians￿ reports on the record-of-visit
form. Similarly, over the 18 months, the total time for follow-up
visits was longer in the general practice group (mean 35.6 min)
than in the hospital group (mean 20.7 min) (difference 14.9; 95%
CI 11.3—18.4; P < 0.001).
Health service costs per patient
The mean total cost and cost per visit was significantly less per
patient in the general practice group than in the hospital group
(Table 1). Although there was no difference between groups in the
overall cost of diagnostic tests per patient (Table 1), there were
significant differences between groups in the costs of individual
diagnostic tests (Table 2). General practitioners ordered more of
particular diagnostic tests than did specialists, resulting in signifi-
cantly greater costs for chest radiographs, blood tests [full blood
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*An assurance of confidentiality was requested and given to the study hospitals
regarding unit costs. For this reason, only the average of the costs for the study
hospitals is given.
￿National average wage rates for manual and non-manual labour taken from New
Earnings Survey (1994).count (FBC), erythrocyte sedimentation rate (ESR) and liver
enzymes] and mammograms (Table 2).
Health service costs per visit
Over the 18 months of the study, there was a total of 501 follow-up
visits in the general practice group and 397 visits in the hospital
group. The general practice patients were seen significantly more
often than were the specialist patients. Although the mean cost per
visit in general practice was significantly less, the mean cost of
diagnostic tests per visit was similar in the two groups (Table 3).
The lower cost in general practice was attributable to lower physi-
cians￿ costs per visit (Table 3).
Patient costs
There were more patients in paid employment in the general practice
group than in the hospital group (Table 4). For those patients in paid
employment, more in the hospital group took time off work,
although there was no difference between groups in the proportion
losing wages to attend the follow-up appointment (Table 4). Of note,
no more than four patients in either group incurred lost income, and
only three patients in the hospital group incurred costs for child care
(Table 4). Significantly more patients in the general practice group
were able to walk to their appointment (Table 4), and significantly
more patients in the hospital group incurred out-of-pocket expenses
for car parking (Table 4). With respect to accompanying persons,
there were no differences between general practice and hospital
group in the proportion who took time off work [4 out of 140 (2.9%)
vs 9 out of 126 (7.1%) (P = 0.21) respectively] or lost wages [1 out
of 140 (0.7%) vs 3 out of 126 (2.4%) (P = 0.41) respectively].
Patients in the general practice group spent significantly less
time getting to and from their appointment and waiting to see the
doctor than patients in the hospital group. Patients in the general
practice group, however, spent significantly more time with the
doctor than patients in the hospital group (Table 5). For example,
based on patients￿ reports in the cost questionnaire, an average
follow-up appointment in the general practice group took a total of
52.6 min (of which 12.8 min were spent with the doctor) compared
with 82.2 min (of which 6.9 min were spent with the doctor) in the
hospital group (Table 5).
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Table 1 Average costs (£s) per patient by trial group
GP group Hospital group Difference
n = 148 n = 141 GP – Hospital
Resource item Mean (s.d.) Range Mean (s.d.) Range (95% CI)
Cost of visits 40.9 5.8–143.8 174.1 62.0–558.0 –133.2*
(20.1) (85.1) (–147.8;–118.7)
Cost of tests 23.8 0.0–158.2 20.9 0.0–204.9 2.9
(29.7) (36.3) (–4.8; 10.6)
Total costs 64.7 5.8–301.9 195.1 62.0–737.4 –130.4*
(42.8) (107.4) (–149.1;–111.6)
*P < 0.001.
Table 2 Mean frequency and cost of each type of test by trial groupa
Test Unit Mean frequency and costs (£s)
cost GP group Hospital group Difference
(£s)b No./Pt Cost/Pt No./Pt Cost/Pt (95% CI) P-Value
–0.001 0.959
Biopsy 19.52 0.02 0.39 0.021 0.42 (–0.039; 0.037)
–0.045 0.223
Bonescan 79.08 0.054 4.27 0.099 7.83 (–0.118; 0.028)
0.105 0.007
Chest radiograph 13.17 0.162 2.13 0.057 0.75 (0.029; 0.182)
0.112 0.002
Full blood count 5.47 0.148 0.81 0.036 0.19 (0.042; 0.182)
0.087 0.002
Liver enzymes 6.84 0.108 0.74 0.021 0.14 (0.031; 0.143)
0.138 0.043
Mammograms 26.37 0.493 13.00 0.355 9.36 (0.004; 0.273)
–0.029 0.188
Needle biopsy (FNA) 21.76 0.014 0.30 0.043 0.93 (–0.072; 0.014)
0.007 0.592
Abdominal ultrasound 23.15 0.014 0.32 0.007 0.16 (–0.017; 0.03)
0.011 0.720
Radiograph (other) 20.32 0.068 1.38 0.057 1.15 (–0.049; 0.07)
0.054 0.004
ESR 9.00 0.054 0.49 0 0 (0.017; 0.091)
aGP group, n = 148; hospital group, n = 141; bunit costs are the average of the unit costs provided by the study hospitals for each diagnostic test.1230 E Grunfeld et al
British Journal of Cancer (1999) 79(7/8), 1227–1233 © Cancer Research Campaign 1999
Table  3  Average cost (£s) per visit by trial group
GP group Hospital group Difference
n= 501 n = 397 GP – hospital
Resource item Mean (s.d.) Range Mean (s.d.) Range (95% CI)
Cost of physician 12.1 3.5–51.8 62.0 62.0–62.0 –49.9*
(4.6) (–50.4;–49.5)
Cost of tests 6.9 0.0–105.5 7.2 0.0–111.8 –0.3
(14.8) (17.8) (–2.4; 1.9)
Total cost per visit 19.0 3.5–128.5 69.2 62.0–173.8 –50.2*
(16.6) (17.8) (–52.5; –47.9)
*P < 0.001.
Table 4Midtrial patient resource events by trial group
GP group Hospital group
n= 140c n= 126c
Parameter No. % No. % P-Value
Employed 65 47.8 36 31.0 0.023
Not employed 71 52.2 80 69.0
Took time off work 21 32.3 22 61.1 0.006
No time off work 44 67.7 14 38.9
Lost wages 3 4.6 4 11.4 0.24
No lost wages 62 95.4 31 88.6
Transportation to appointmenta
Walk 45 32.4 2 1.6
Bus 11 7.9 18 14.8 0.000
Car 80 57.6 97 79.5
Other 3 2.2 5 4.1
Out-of-pocket expenses
Yesb 3 2.4 12 11.0 0.008
No 121 97.6 97 89.0
Need for child care
Yes – – 3 2.6 0.06
No 135 100.0 114 97.4
aAs the same mode of transportation was used for journey to and from appointment, only data for transportation to appointment
shown. bIn all cases, out-of-pocket expenses were for car parking. cFor some parameters No. does not sum to ‘n’ because of
missing data.
Table 5Midtrial patient time by trial group
Parameter Group No. Time (min) Difference in means
Mean (s.d.) (95% CI)
Time to get to appointment GP 135 13.1 (8.3) –13.56*
Hospital 120 26.7 (15.9) (–16.65; –10.37)
Time to get back from appointment GP 138 13.6 (8.6) –14.12*
Hospital 118 27.7 (15.3) (–17.12; –11.12)
Time waiting to see the doctor GP 136 13.0 (10.7) –10.3*
Hospital 119 23.3 (19.9) (–14.2; –6.5)
Time with the doctor GP 138 12.8 (5.8) 5.9*
Hospital 121 6.91 (4.1) (4.7; 7.2)
GP 131 52.6 (22.1) –29.6*
Total time for appointment Hospital 115 82.2 (31.8) (–36.5; –22.8)
*P < 0.001.Cost minimization analysis
The total direct health care and patient costs and time costs for the
study cohort during the 18 months of follow-up are reported in
Table 6. Despite fewer visits per patient in the hospital group, the
large difference in direct medical costs between groups was due to
the greater cost of specialist outpatient visits. The difference in
direct non-medical costs to patients was due to higher costs
incurred by patients in the hospital group for car parking. Patient
travel costs (other than car parking) were similar between groups
because the larger costs incurred by patients in the hospital group
were offset by fewer follow-up visits. Time costs in the form of
wages foregone for patients and accompanying persons were
greater in the hospital group because of the greater time taken to
attend a specialist outpatient visit. This was the case despite
similar proportions in each group taking time off work and fewer
follow-up visits in the hospital group.
DISCUSSION
Health service costs
The calculation of health service costs is based on unit costs for
diagnostic tests and outpatient consultations obtained directly
from the institutions involved in the study, both of which were
district general hospitals in central England. Uncertainty exists as
to whether the unit costs provided by the institutions reflect the
real costs of the services, and whether they are typical of costs
elsewhere in England. The variation in costs in different districts in
England (and elsewhere) may result in less cost savings for some
institutions and more for others. To facilitate comparison with
other settings, data on the quantity as well as the cost of health
service resource use are provided (Drummond and Davies, 1991;
Drummond and Jefferson, 1996). This study provides data on
the average frequency and length of visits, and frequency of
diagnostic testing during the routine follow-up period. Hence, this
study provides purchasers in district health authorities with the
means to calculate for themselves the costs associated with the
different follow-up strategies. Although a formal sensitivity
analysis was not conducted, even reducing the unit cost of an
outpatient consultation by 50% would have minimal impact on the
overall findings of the cost analysis.
The cost calculations are based on average costs rather than
marginal costs because average costs provide a better estimate of
the cost of services affecting a large number of facilities
(Drummond and Jefferson, 1996). Thus, the use of average costs
enhances the generalizability of the results (Drummond and
Jefferson, 1996), but may overestimate the costs in the short-term
when compared with a calculation based on marginal costs
(Robinson, 1993).
An important finding of this study is that general practitioners
ordered more diagnostic tests than specialists. GPs were provided
with guidelines that mammograms were the only investigation
recommended routinely. Nevertheless, they ordered five times as
many FBCs and liver enzymes, three times as many chest radi-
ographs, and eight times as many ESRs. This finding is not
surprising because it has been suggested that GPs might order
diagnostic tests more frequently than specialists because of lack of
confidence in their clinical skills. One other possible explanation
is that these tests were ordered because of a co-morbidity for
which the GP was also following the patient.
No previous study has compared the cost of specialist follow-up
with follow-up in primary care. Other reports have compared
￿intensive￿ with ￿minimalist￿ follow-up strategies (Schapira, 1993;
Mapelli et al, 1995; Virgo et al, 1995). Although the ￿minimalist￿
follow-up strategy in those reports is similar to the control arm of
this study (periodic examination and routine mammograms), the
experimental arm goes one step further by providing ￿minimalist￿
follow-up in primary care. The results of the economic evaluation
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Table 6 Average costs for 18 months of follow-up by trial group
GP group costs (£s) Hospital group (£s)
n = 148 n = 148
(average number of visits = 3.39) (average number of visits = 2.81)
Direct medical costs
Diagnostic tests 3526.84 3100.60
Physician consultations 6053.20 25771.24
Direct non-medical costsa
Patient travelb 817.80 748.58




Accompanying person 20.76 80.38
Total 10488.01 30109.10
aPatient costs based on data from midtrial assessment. bCalculation based on reported travel costs to clinics and GP offices uprated to 1994 prices. Average
cost to GP office £1.63; average cost to clinic £1.80, assuming approximate proportion of patients driving to GP office is 42% and driving to clinic is 77%
(Wilson, 1991). Travel cost per visit multiplied by number of patients and average number of visits per patient in each group cCalculation based on out-of-pocket
expenses reported by patients at midtrial multiplied by average number of visits per patient in each group. dValuation of leisure time and work time costs (other
than lost wages) not included in this analysis. eCalculation based on average total time costs of patients at midtrial (gross hourly wage for non-manual labour ´
average total time for appointment) multiplied by number of patients reporting lost wages (for self or accompanying person) multiplied by average number of
visits per patient in each group. Wages based on 1994 gross wages for non-manual employment (almost all patients reporting lost wages were in non-manual
labour). (New Earnings Survey, 1994.)of this study show that the lower cost of the experimental strategy
is primarily attributable to the lower cost of a general practitioner
consultation compared with a specialist consultation in hospital
clinics. This cost saving, however, might be counterbalanced by
the documented increased use of diagnostic tests by GPs, and the
expected (but not documented) further costs of false-positive test
results. Before it can be concluded with certainty that primary care
follow-up is the less costly follow-up strategy, further investiga-
tion will need to be carried out.
Patients costs
In this study, data were collected on direct costs to patients (travel,
child care, out-of-pocket expenses), time costs (wages lost to
patients and accompanying persons), and the time taken for a
follow-up visit. Lost wages were valued according to national
average wage rates. The time taken for a follow-up visit, however,
was significantly greater in the hospital group than in the GP
group. In this study, no monetary value was given for the time
taken for a follow-up visit. Although it is recognized that there is
an opportunity cost associated with time forgone to attend a
follow-up visit (Robinson, 1993; Sculpher and Buxton, 1993),
valuation of this time was not undertaken because of the un-
resolved controversy over the best way to value leisure time costs
and non-working time costs (Drummond et al, 1997). Further
research is warranted to model — according to the different
approaches to valuing time — the private time costs associated with
the different follow-up strategies. The high prevalence of breast
cancer and the length of current follow-up practices suggests that
private time costs will have a significant impact when viewed
from the societal perspective (Sculpher and Buxton, 1993;
Drummond et al, 1997). The finding of this study that significantly
more patients walked to general practice visits is consistent with
other studies comparing GP and hospital-based screening clinics
(Sculpher and Buxton, 1993). Similarly, the finding that a minority
of patients in either group took time off work and a very small
minority lost wages is consistent with other studies (Sculpher and
Buxton, 1993).
In a comparative study of specialist vs. shared primary
care/specialist paediatric cancer care, the greatest proportion of
saved costs was associated with patient non-medical costs in the
form of travel costs, opportunity costs of time and lost wages
(Strayer et al, 1980). When one therapy results in better outcomes
than another, patients will choose the best therapy regardless of
costs. When clinical outcomes are equivalent, however, personal
costs will influence patients￿ decisions about health care alter-
natives (Strayer et al, 1980). This may be particularly true for
screening programmes in which benefits are less tangible and
personal costs may prove to be economic barriers to the use of
such programmes (Sculpher and Buxton, 1993). The possibility
that a proportion of patients may not be attending regular follow-
up in specialist clinics because of economic barriers has never
been raised in the literature on follow-up. (As noted previously,
follow-up can be viewed as a screening programme for recurrent
disease.) Although the data from this study cannot illuminate this
point (as study patients were already regularly attending for
follow-up), it is an interesting possibility that GP follow-up
may make the follow-up programme available to a broader
range of patients, who may otherwise be deterred by economic
barriers.
CONCLUSIONS
The RCT showed no increase in the clinical outcomes of delay in
diagnosing recurrence and reinitiating specialist care as a result of
primary care follow-up (Grunfeld et al, 1996). Process measures
of the quality of clinical care such as frequency and length of visits
(Health Services Research Group, 1992) were superior in primary
care.
The cost of physician visits and patient costs were lower in
primary care. However, there was no difference in the total costs of
diagnostic tests, with particular tests being performed more
frequently in primary care than in specialist care. Thus, the lower
health service costs of primary care follow-up were attributable to
the lower cost of a physician visit. The impact of excess costs of
tests and of false-positive test results would have to be evaluated
before it can be concluded with certainty that primary care follow-
up is the less costly option overall. These excess costs may
counterbalance the lower costs of a visit in countries where the
cost differential between primary care physicians and specialist
physicians is not as great as it is in the UK.
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